MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY

Location

Founded

1989-12-19

Website

https://www.medtronic.com

Risk Signals

4873 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Surgical and Medical Instruments and Apparatus, Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Filter risk signals by topic

Select a theme below to explore the company’s news mentions in specific risk areas.

Stock Market Events (766) New Product Release (624) Acquisition Announcements (618) Financial Reporting (615) Market Trends (581) Inter-Organizational Collaborations (510) Legal Proceedings (490) Earnings Reports & Warnings (401) Business Growth Initiatives (376) Executive Leadership Changes (375) Research and Development (356) Investment Strategies (346) Competitive Market Dynamics (338) Equity Analysis & Ratings (279) Research Breakthroughs (264) Product Recall (247) Corporate Awards and Recognitions (194) Corporate Deals (174) Recruitment Activities (172) Access and Affordability Initiatives (162) Business Resilience Planning (138) Workforce Reductions (137) Quality Assurance & Safety (131) Economic Indicators (125) Political and Economic Developments (119) Intellectual Property Rights (119) Regulatory Updates (115) Public Health Crisis Response (115) Corporate Governance Policies (111) Sustainable Product Design (106)

Recent Articles about MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY

Live alerts from global media, monitored by Business Radar

2025-04-07 (aktien-mag.de)

Beta Bionics revolutionizes the insulin pump market with the only adaptive closed loop algorithm!

The medical technology company Beta Bionics (BBNX) only completed its IPO on January 29 and wants to revolutionize the treatment of type 1 diabetes with the ILET insulin pump system. As a fully automated bionic pancreas (pancreas) in the United States, this is intended to address a $ 2 billion pump market and 1.8 million affected patients. ILET is considered the first and only adaptive closed loop algorithm for automated insulin management approved by the FDA. With the input of body weight alone, the algorithms can automate insulin dosage. Previous hybrid-closed loop solutions by competitors Insulet, Medtronic and Tandem Diabetes Care are much more complex by specifying carbohydrates for meals, manually calculated correction doses or adapting the insulin basal rate.